United Therapeutics Beat Consensus Estimates

United Therapeutics (UTHR) reported earnings of $6.63 per share on revenue of $794.40 million for the first quarter ended March 2025. The consensus earnings estimate was $6.29 per share on revenue of $726.06 million. The company beat consensus estimates by 5.41% while revenue grew 17.22% on a year-over-year basis.

United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.